Keyword: Sun Pharmaceutical
Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.
After years of effort and a couple of reinspections, India’s Sun Pharma has been unable to satisfy the FDA's expectations for its key plant.
Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.
Takeda buys up TiGenix; some foreign drugs may be approved in China in 2018; Asian firms circle Sanofi's European generics unit.
Sun Pharmaceuticals has increased its ownership in its Malaysia production venture twice in three months and now holds an 85.9% share.
Here's your pharma manufacturing news of note.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Sun Pharmaceuticals said the FDA has cleared its manufacturing facility at Dadra that had received a warning letter from the agency earlier this year.
Sun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a of a host of issues that contributed to a 74% profit slide.
Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.